Solid Biosciences (NASDAQ:SLDB) Upgraded to Strong-Buy at Truist Financial

Solid Biosciences (NASDAQ:SLDB) was upgraded by research analysts at Truist Financial to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

SLDB has been the subject of several other reports. Chardan Capital reaffirmed a “buy” rating and issued a $15.00 price target on shares of Solid Biosciences in a report on Friday, March 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of Solid Biosciences in a research note on Friday, March 20th. Citigroup reissued a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. lifted their target price on Solid Biosciences from $11.00 to $12.00 and gave the company an “overweight” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Solid Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $16.09.

Solid Biosciences Price Performance

Solid Biosciences stock opened at $7.23 on Wednesday. The company has a market cap of $563.29 million, a PE ratio of -3.58 and a beta of 2.65. The company has a fifty day moving average price of $6.53 and a two-hundred day moving average price of $5.82. Solid Biosciences has a 12 month low of $2.41 and a 12 month high of $8.72.

Solid Biosciences (NASDAQ:SLDB) last released its earnings results on Thursday, March 19th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.01. Equities research analysts anticipate that Solid Biosciences will post -2.84 earnings per share for the current year.

Insider Activity at Solid Biosciences

In related news, CEO Alexander Cumbo sold 80,258 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $6.44, for a total value of $516,861.52. Following the sale, the chief executive officer owned 270,931 shares of the company’s stock, valued at $1,744,795.64. This trade represents a 22.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Kevin Tan sold 26,837 shares of Solid Biosciences stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $6.44, for a total transaction of $172,830.28. Following the completion of the sale, the chief financial officer owned 108,984 shares in the company, valued at approximately $701,856.96. This represents a 19.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 597,672 shares of company stock valued at $3,816,546. Company insiders own 1.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vestal Point Capital LP grew its position in Solid Biosciences by 95.5% in the 4th quarter. Vestal Point Capital LP now owns 5,815,000 shares of the company’s stock worth $32,797,000 after purchasing an additional 2,840,000 shares during the last quarter. Armistice Capital LLC raised its holdings in shares of Solid Biosciences by 179.1% during the fourth quarter. Armistice Capital LLC now owns 2,612,000 shares of the company’s stock valued at $14,732,000 after buying an additional 1,676,000 shares during the last quarter. Nantahala Capital Management LLC raised its holdings in shares of Solid Biosciences by 505.4% during the second quarter. Nantahala Capital Management LLC now owns 1,703,336 shares of the company’s stock valued at $8,295,000 after buying an additional 1,421,968 shares during the last quarter. Monashee Investment Management LLC acquired a new position in shares of Solid Biosciences during the fourth quarter worth approximately $7,613,000. Finally, Geode Capital Management LLC boosted its position in shares of Solid Biosciences by 184.5% during the second quarter. Geode Capital Management LLC now owns 1,510,153 shares of the company’s stock worth $7,356,000 after buying an additional 979,294 shares during the period. 81.46% of the stock is owned by institutional investors and hedge funds.

Key Solid Biosciences News

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: JPMorgan raised its price target on SLDB to $12.00 from $11.00 and moved the stock to an “Overweight” stance — implying roughly a 66% upside from the referenced $7.23 level. This upgrade signals increased conviction from a large Wall Street shop and likely contributed to buying interest. Benzinga
• Positive Sentiment: HC Wainwright reiterated a “Buy” and lifted near-term EPS forecasts across multiple quarters and fiscal years (Q1–Q4 2026 and FY2026) while maintaining a $20 price target. They also issued later-year upside (FY2029–FY2030 projected profitability), trimming FY2026 losses significantly vs. prior forecasts — an analyst view that supports a more constructive growth/profitability outlook. Solid Biosciences Earns Buy Rating from HC Wainwright
• Neutral Sentiment: Reported short-interest data for March appears anomalous (shows 0 shares and NaN changes). Because the figures are likely erroneous or incomplete, they provide no clear signal about potential short-squeeze dynamics or bearish positioning at this time.

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.